ConductScience.org, home

Comparison · NCT00745901-da823472

NGM/25mcg EE vs DRSP/20mcg EE: Number of Participants With Breakthrough Bleeding/Spotting Cycle 1

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. NGM/25mcg EE vs DRSP/20mcg EE: Number of Participants With Breakthrough Bleeding/Spotting Cycle 1. Trial comparisons, record NCT00745901-da823472. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00745901-da823472

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3210.2550.396wilson
Risk in group 20.3350.2680.41wilson
Risk difference, group 1 minus group 2-0.0141-0.1140.0863newcombe hybrid score
Risk ratio, group 1 over group 20.9580.7041.3log
Odds ratio, group 1 over group 20.9380.5931.48log
Number needed to treat, for one fewer participant with the outcome on NGM/25mcg EE than on DRSP/20mcg EE70.8from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1NGM/25mcg EENGM=norgestimate; EE=ethinyl estradiol. Days 1-7: 180 mcg NGM/25 mcg EE; Days 8-14: 215 mcg NGM/25 mcg EE; Days 15-21: 250 mcg NGM/25 mcg EE; Days 22-28: inert ingredients53165OG000
Group 2DRSP/20mcg EEDRSP=drospirenone; EE=ethinyl estradiol. Days 1-24: 3 mg DRSP/20 mcg EE; Days 25-28: inert ingredients56167OG001

Outcome

Type
PRIMARY
Title
Number of Participants With Breakthrough Bleeding/Spotting Cycle 1
Description
Breakthrough bleeding/spotting is any bleeding or spotting during active pills excluding days contiguous with withdrawal bleeding or continual withdrawal bleeding.
Time frame
Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)
Population
Efficacy Analysis Population: all randomized patients who took study drug and for whom there was post-baseline blood loss data after Day 7.

Source ClinicalTrials.gov

Trial

Title
Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females
NCT number
NCT00745901
Phases
PHASE4
Conditions
Contraception
Interventions
Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Results first posted
2010-05-25

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00745901-da823472